O'Sullivan Miriam 4
4 · BOSTON SCIENTIFIC CORP · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific (BSX) SVP Miriam O'Sullivan Exercises Options, Receives Awards
What Happened Miriam O'Sullivan, SVP & Chief Human Resources Officer at Boston Scientific (BSX), had several equity actions reported for 2026-02-12. The Form 4 shows conversion/exercise of derivative awards totaling 961 shares (reported both as acquired and disposed in the filing) and a tax-withholding disposition of 338 shares sold at $74.12 for $25,053. She was also granted awards totaling 4,722 and 11,143 shares (15,865 total awards) and received a separate option grant subject to vesting. The acquisitions are reported at $0.00 per share, which is typical for restricted stock unit (RSU) conversions/awards rather than a market purchase.
Key Details
- Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (5 days after the transactions — outside the usual 2-business-day window for Form 4 filings).
- Tax withholding: 338 shares disposed at $74.12 per share, net proceeds reported as $25,053 (code F).
- Derivative activity: 961 shares reported as exercised/converted (code M) with both an “acquired” and a “disposed” entry in the filing.
- Awards granted: 4,722 shares (A) and 11,143 shares (A) — total 15,865 awarded (reported at $0.00).
- Shares owned after transaction: not provided in the supplied data.
- Footnotes (from the filing):
- F1: Each RSU represents a commitment to issue one share.
- F2: One award vests in four equal annual installments beginning Feb 12, 2025.
- F3: One award vests in four equal annual installments beginning Feb 12, 2027.
- F4: Option grant vests in four equal annual installments beginning Feb 12, 2027.
Context The filing primarily reflects awarded/vested equity (RSUs/options) and tax withholding rather than an open-market sale or purchase. The $25k figure is the value of shares withheld/surrendered to satisfy tax obligations; this is routine for RSU vesting and does not necessarily indicate a discretionary sale. The awards and option grants are subject to future vesting schedules per the footnotes, so they do not represent immediately tradable stock for the full amounts reported.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-12+961→ 15,758 total - Tax Payment
Common Stock
2026-02-12$74.12/sh−338$25,053→ 15,420 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-02-12−961→ 1,924 totalExp: 2028-02-12→ Common Stock (961 underlying) - Award
Restricted Stock Units
[F1][F3]2026-02-12+4,722→ 4,722 totalExp: 2030-02-12→ Common Stock (4,722 underlying) - Award
Stock Option (Right to Buy)
[F4]2026-02-12+11,143→ 11,143 totalExercise: $74.12Exp: 2036-02-12→ Common Stock (11,143 underlying)
- 1,731(indirect: By Spouse)
Common Stock
Footnotes (4)
- [F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F2]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
- [F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
- [F4]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.